Clinicopathologic characteristics and survival of MDS patients according to circulating let-7a and miR-16 levels
| Characteristics . | let-7a . | miR-16 . | ||||
|---|---|---|---|---|---|---|
| Low . | High . | P . | Low . | High . | P . | |
| Age, y | .52 | 1.00 | ||||
| ≥ 72 | 23 (61) | 6 (50) | 23 (59) | 6 (55) | ||
| < 72 | 15 (39) | 6 (50) | 16 (41) | 5 (45) | ||
| Sex | .18 | .73 | ||||
| Male | 28 (74) | 6 (50) | 26 (67) | 8 (73) | ||
| Female | 10 (26) | 6 (50) | 13 (33) | 3 (27) | ||
| WHO classification | .59 | .38 | ||||
| MDS-U | 0 (0) | 1 (8) | 0 (0) | 1 (9) | ||
| MDS del(5q) | 1 (3) | 0 (0) | 1 (3) | 0 (0) | ||
| RCMD | 19 (50) | 6 (50) | 21 (54) | 4 (36) | ||
| RARS | 1 (3) | 0 (0) | 1 (3) | 0 (0) | ||
| RAEB-1 | 10 (26) | 3 (25) | 10 (26) | 3 (27) | ||
| RAEB-2 | 7 (18) | 2 (17) | 6 (15) | 3 (27) | ||
| IPSS risk score | .90 | .60 | ||||
| Low | 8 (21) | 2 (17) | 8 (21) | 2 (18) | ||
| INT-1 | 14 (37) | 5 (42) | 16 (41) | 3 (27) | ||
| INT-2 | 16 (42) | 5 (42) | 15 (38) | 6 (55) | ||
| Median survival, mo (range) | ||||||
| Progression-free survival | — (12-75) | 12 (2-12) | < .001 | — (13-75) | 12 (2-12) | < .001 |
| Overall survival | 42 (7-75) | 8 (3-41) | < .001 | 42 (5-75) | 12 (3-41) | .001 |
| Characteristics . | let-7a . | miR-16 . | ||||
|---|---|---|---|---|---|---|
| Low . | High . | P . | Low . | High . | P . | |
| Age, y | .52 | 1.00 | ||||
| ≥ 72 | 23 (61) | 6 (50) | 23 (59) | 6 (55) | ||
| < 72 | 15 (39) | 6 (50) | 16 (41) | 5 (45) | ||
| Sex | .18 | .73 | ||||
| Male | 28 (74) | 6 (50) | 26 (67) | 8 (73) | ||
| Female | 10 (26) | 6 (50) | 13 (33) | 3 (27) | ||
| WHO classification | .59 | .38 | ||||
| MDS-U | 0 (0) | 1 (8) | 0 (0) | 1 (9) | ||
| MDS del(5q) | 1 (3) | 0 (0) | 1 (3) | 0 (0) | ||
| RCMD | 19 (50) | 6 (50) | 21 (54) | 4 (36) | ||
| RARS | 1 (3) | 0 (0) | 1 (3) | 0 (0) | ||
| RAEB-1 | 10 (26) | 3 (25) | 10 (26) | 3 (27) | ||
| RAEB-2 | 7 (18) | 2 (17) | 6 (15) | 3 (27) | ||
| IPSS risk score | .90 | .60 | ||||
| Low | 8 (21) | 2 (17) | 8 (21) | 2 (18) | ||
| INT-1 | 14 (37) | 5 (42) | 16 (41) | 3 (27) | ||
| INT-2 | 16 (42) | 5 (42) | 15 (38) | 6 (55) | ||
| Median survival, mo (range) | ||||||
| Progression-free survival | — (12-75) | 12 (2-12) | < .001 | — (13-75) | 12 (2-12) | < .001 |
| Overall survival | 42 (7-75) | 8 (3-41) | < .001 | 42 (5-75) | 12 (3-41) | .001 |
Values are n (%) except for median survival.
WHO indicates World Health Organization; MDS-U, MDS-unclassified; MDS del(5q), MDS associated with isolated del(5q); RCMD, refractory cytopenia with multilineage dysplasia; RARS, refractory anemia with ring sideroblasts; RAEB, refractory anemia with excess blasts; and INT, intermediate.